Pure Global

Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African Americans Study (GENE-FORECAST): Sodium Intervention Trial (SIT) - Trial NCT04717336

Access comprehensive clinical trial information for NCT04717336 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by National Human Genome Research Institute (NHGRI) and is currently Recruiting. The study focuses on Cardiovascular Disease. Target enrollment is 150 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT04717336
Early Phase 1
Recruiting
other
Trial Details
ClinicalTrials.gov โ€ข NCT04717336
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African Americans Study (GENE-FORECAST): Sodium Intervention Trial (SIT)
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study(GENE-FORECAST): Sodium Intervention Trial (SIT)/GENE-FORECAST SIT

Study Focus

Cardiovascular Disease

SODIUM CHLORIDE

Interventional

other

Sponsor & Location

National Human Genome Research Institute (NHGRI)

National Institutes of Health Clinical Center (CC)

Bethesda, United States of America

Timeline & Enrollment

Early Phase 1

Jan 22, 2021

Jul 03, 2023

150 participants

Primary Outcome

What effect does increase dietary sodium intake have on vascular function and microbiome?

Summary

Background:
 
 Hypertension is a risk factor for heart disease. Low-sodium diets rich in fruits, vegetables,
 and other healthy foods are a good way to reduce blood pressure in people with hypertension.
 Researchers want to learn more about why African Americans seem to have the greatest benefit
 from certain dietary interventions.
 
 Objective:
 
 To better understand the body s response to adding more salt to the diet.
 
 Eligibility:
 
 U.S.-born African American adults ages 21 to 65 who are in good general health and took part
 in the GENE-FORECAST.
 
 Design:
 
 Participants will be screened with a medical history and physical exam. If needed, they will
 take a pregnancy test. These tests will be repeated during the study.
 
 Each day for 2 weeks, participants will take 3 capsules that contain either placebo or salt.
 Then they will take no pills for 3 weeks. Then they will take placebo or salt capsules for 2
 more weeks.
 
 Participants will talk about the foods and drinks they have consumed over the past 24 hours.
 They will take a survey about their physical activity and sleep.
 
 Participants will complete taste tasks to obtain their responses to sweetness or saltiness.
 Sucrose and salt detection thresholds and preferences will be assessed.
 
 Participants will give blood and urine samples. Saliva samples will be collected from their
 mouth by passive drool or by spitting into a sterile tube. Skin samples will be collected
 from behind their ears and the inner part of their elbow, using sterile swabs. Participants
 will get kits to collect stool samples at home.
 
 Participants will have 4 study visits over 7 weeks.

ICD-10 Classifications

Cardiovascular disease, unspecified
Hypertensive heart disease
Heart disease, unspecified
Atherosclerotic cardiovascular disease, so described
Atherosclerotic heart disease

Data Source

ClinicalTrials.gov

NCT04717336

Non-Device Trial